Nuvation Bio Inc. (NUVB)
NYSE · USD · Healthcare · Biotechnology
$4.51 (-1.31%) as of
Key statistics
- Market cap
- 1.58B
- Forward P/E
- -300.67
- EPS (TTM)
- -0.4400
- Dividend yield
- 0.00%
- 52-week range
- 3.9200 – 9.7500
- Beta
- 1.62
- Revenue (TTM)
- 169.9M
- Profit margin
- -88.19%
- Analyst target
- $13.00
- Volume
- 3.66M
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 305
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.